<p>Immutep Ltd. announced that it has achieved 50% enrolment in its global TACTI-004 (KEYNOTE-F91) Phase III trial for first-line treatment of advanced/metastatic non-small cell lung cancer (1L NSCLC). The trial is evaluating the combination of eftilagimod alfa (efti) with KEYTRUDA® (pembrolizumab) and chemotherapy. To date, 378 patients have been enrolled globally, with more than 140 clinical sites activated across 27 countries. A futility analysis is scheduled for the first quarter of 2026, and completion of patient enrolment is expected in the third quarter of 2026. Results from the study have not yet been presented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Reuters

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Ark Genomic Revolution ETF

VanEck Biotech ETF

Immutep

iShares Biotechnology ETF

Immutep Ltd

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Immutep Reaches 50% Enrollment Milestone in Global Phase III TACTI-004 Trial for First-Line NSCLC